In a cardiac catheterization lab, the procedure ends when the wire is out. The real work for the nursing staff, however, is just beginning. For the next several hours, they must manually apply and adjust pressure to the patient's radial artery access site in the wrist, a repetitive and time-consuming task critical to preventing bleeding complications. It is this unglamorous, post-procedural chore that Warsaw-based Simplicardiac is trying to automate with its SimpliRadial compression band, betting that a smarter device can improve safety and free up clinical time in one of the hospital's most resource-intensive units [simplicardiac.com].
The clinical wedge in post-cath care
Simplicardiac's focus is arterial-access-site management, a niche but vital segment of interventional cardiology. The company's principal product is a compression band designed for procedures performed via the radial artery in the wrist, an approach that has become the preferred method for coronary angiography and stenting due to lower bleeding risks and faster patient mobility compared to the femoral artery. The band's proposed innovation is automation: integrating sensors and feedback mechanisms to provide real-time monitoring of hemostasis, theoretically reducing the need for constant nurse supervision [simplicardiac.com]. The company has secured international patent protection for its "Medical Device for Blood Vessel Compression" and is currently implementing a European Union-co-financed project valued at nearly PLN 870,000 (approximately $220,000) to extend that patent shield [simplicardiac.com].
A founder duo of commercial and clinical expertise
The company's leadership reflects a deliberate blend of commercial drive and deep clinical insight. Co-founder and CEO Andrzej Białkowski-Miler is a biotech and medtech entrepreneur with over 16 years in technology transfer and startup development, having also founded a consulting firm focused on the sector [LinkedIn]. The clinical vision comes from co-founder Mariusz Kruk, MD, PhD, the inventor listed on the device's patent and a professor at Poland's National Institute of Cardiology in Warsaw [patents.google.com]. His background in cardiology and clinical trials grounds the company's development in practitioner experience, a credential that carries weight when presenting at forums like the "Cath Lab of the Future" session at the TCT Innovation conference in Washington in late 2024 [simplicardiac.com].
NCBR Loan (2020) | 1.2 | M PLN
EU Co-Financed Project | 0.869 | M PLN
Navigating a path to the market
Simplicardiac's financial journey illustrates the complex funding landscape for European hardware medtech. The company initially received a PLN 1.2 million loan from Poland's National Centre for Research and Development (NCBR) [Onet, May 2020]. This was followed by reported investor financing in 2023, which the company stated was used to repay that public loan and fund a push toward the commercial market [Biotechnologia.pl, May 2023]. While specific equity round details are not public, the company's current hiring focus offers clues to its priorities. Open roles for a Regulatory Affairs Specialist and a DevOps Engineer signal a dual focus on securing the necessary CE Mark for European market entry and building the digital infrastructure for a connected device [simplicardiac.com].
The competitive field is occupied by established players, but Simplicardiac is positioning its device on the promise of automation and data.
| Competitor | Product | Key Differentiation |
|---|---|---|
| Terumo | TR Band | Manual, disposable compression device; global standard. |
| Merit Medical | PreludeSYNC | Radial compression device with a syncing mechanism for pressure. |
| Simplicardiac | SimpliRadial | Aims for automated, sensor-driven pressure management with monitoring. |
The regulatory and reputational landscape
Any medtech company's success is inextricably linked to its regulatory pathway and the trust of the clinical community. For Simplicardiac, the road includes a past controversy that adds a layer of scrutiny. Polish press reports from 2020 questioned the legality of the initial NCBR loan due to the company's ownership links to Szumowski Investments, an entity owned by the brother and wife of a former Polish health minister [Onet, May 2020]. The company was included in broader reporting about business links involving the Szumowski family [Polityka, June 2020]. While the company obtained subsequent investor financing to repay that loan, this history is a part of the public record that potential commercial partners and regulatory bodies may consider.
The company's most credible near-term risk is not the technology concept, but the execution of a regulated commercial launch. The market entry plan hinges on a few critical, sequential steps:
- Regulatory clearance. Securing a CE Mark is the non-negotiable first gate, a process the new Regulatory Affairs hire is meant to shepherd.
- Clinical validation. Peer-reviewed data demonstrating non-inferiority to existing manual compression, plus tangible reductions in nurse time or complication rates, will be essential for adoption.
- Commercial pilot. A first named hospital deployment would provide the traction signal investors and the market await.
For patients undergoing transradial cardiac catheterization, typically for the diagnosis or treatment of coronary artery disease, the current standard of care is remarkably low-tech. After the procedure, a nurse applies a compression band or device to the puncture site in the wrist. The nurse then manually adjusts the pressure at prescribed intervals, monitors for bleeding or loss of distal pulse, and finally removes the device hours later. It is a safe and effective process, but one that tethers a skilled clinician to a single patient for a significant portion of their shift. Simplicardiac's bet is that this routine, performed millions of times a year globally, is ripe for a gentle automation that makes care both safer and more efficient. The next twelve months will show if their device can move from a conference presentation to a cath lab cart, turning a professor's invention into a practitioner's tool.
Sources
- [simplicardiac.com] Company website | https://simplicardiac.com/
- [LinkedIn] Andrzej Białkowski-Miler profile | https://www.linkedin.com/in/andrzej-bia%C5%82kowski-miler-84b3b914/
- [patents.google.com] Patent for 'Medical device for blood vessel compression' | https://patents.google.com/patent/
- [Onet, May 2020] Report on NCBR loan and ownership links | https://wiadomosci.onet.pl/kraj/lukasz-szumowski-i-afera-z-ncbr-brat-komentuje/p02nwek
- [Biotechnologia.pl, May 2023] Report on investor financing | https://biotechnologia.pl/technologie?month=5&page=50&year=2023
- [Polityka, June 2020] Reporting on business links involving the Szumowski family | https://www.polityka.pl/tygodnikpolityka/kraj/1959028,1,afery-szumowskiego-za-duzo-tego-by-zamiesc-pod-dywan.read